Roadmap for the establishment of a European vaccine R&D infrastructure

Abstract

To consolidate the integration of the fragmented European vaccine development landscape, TRANSVAC - the European Network of Vaccine Research and Development, funded by the European Commission (EC) - has initiated the development of a roadmap through a process of stakeholder consultation. The outcome of this consultation highlighted the need for transnational cooperation and the opportunities that could be generated by such efforts. This cooperation can be achieved through the establishment of a European Vaccine Research and Development Infrastructure (EVRI). EVRI will support cooperation between existing vaccine Research and Development (R&D) organisations from the public and private sector and other networks throughout Europe. It will become sustainable over time by receiving support from multiple sources including the EC, European Union (EU) Member States, European vaccine companies, EVRI partner organisations, and by income generated. Different stakeholders have demonstrated support for the concept of a vaccine infrastructure and agree that such an infrastructure can function as leverage institution between public and private institutions thus making significant contributions to the vaccine field as a whole in its quest to develop vaccines. EVRI will be launched in three phases: preparatory (during which the legal and administrative framework will be defined and a business plan will be elaborated), implementation and operational. If sufficient political and financial commitment can be secured from relevant national and European entities as well as from the private sector and other stakeholders, it could enter into operational phase from 2017 onwards. In conclusion, EVRI can make vaccine R&D more efficient and help address European and global health challenges, help alleviate the burden and spread of infectious diseases, thus contributing to the sustainability of public healthcare systems.

Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges

“…The measurement of the impact of vaccination is not only restricted to public health terms, but also based on economic values: decreasing healthcare spending, reducing lost of labor force, and contributing to the development of the society and the economy . 88 Several developed countries have taken into consideration the pivotal role of vaccination in their respective preventive healthcare programs. The economic benefits of vaccination reveal preventive healthcare as one of the best measures to identify efficiency and profits .…”

Agricultural proteins as multifunctional additives in ZnO‐free synthetic isoprene rubber vulcanizates

“…44 Reversion is characterized by crosslink disappearance and a loss of network structure due to nonoxidative thermal degradation. 45 Sulfur-cured isoprene rubbers commonly exhibit reversion behavior. 46 In the compound formulations tested, a decrease in M t was observed after MH was reached, indicative of reversion ( Figure 1).…”

Double Exponential Evaluation under Non-Pseudo-First-Order Conditions: A Mixed Second-Order Process Followed by a First-Order Reaction

“…It seems likely that double exponential fitting could be useful for determining the rate constant of the first reaction in any series in which that first process is mixed second-order even if the initial concentrations do not obey the classical pseudo-first-order conditions. It seems that there are many potential applications of this possibility [24][25][26][27][28][29][30]. It should also be emphasized that this proposed technique only works if the kinetic scheme is already known with a considerable degree of certainty.…”